{"id":988,"date":"2021-04-30T11:56:49","date_gmt":"2021-04-30T11:56:49","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=988"},"modified":"2021-04-30T11:56:49","modified_gmt":"2021-04-30T11:56:49","slug":"18-apr-2021-otilimab-demonstrated-a-substantial-benefit-in-severe-covid-patients","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/18-apr-2021-otilimab-demonstrated-a-substantial-benefit-in-severe-covid-patients\/","title":{"rendered":"(18 Apr 2021) Otilimab- demonstrated a substantial benefit in severe COVID patients"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p id=\"page-title\" class=\"highwire-cite-title\">A Randomized Trial of Otilimab in Severe COVID-19 Pneumonia (OSCAR)<\/p>\n<p class=\"\">https:\/\/www.medrxiv.org\/content\/10.1101\/2021.04.14.21255475v1<\/p>\n<p class=\"\">NCT04376684- Overall, 806 patients were randomized (1:1); 71% of patients receiving otilimab were alive and free of respiratory failure at Day 28 versus 67% receiving placebo, although this did not reach statistical significance (model-adjusted difference 5.3% [95% CI \u22120.8, 11.4]; p=0.09). However, there was a benefit in the pre-defined \u226570-year age group (model-adjusted difference 19.1% [95% CI 5.2, 33.1]; nominal p=0.009); these patients also had a reduction of 14.4% (95% CI 0.9, 27.9%; nominal p=0.04) in model-adjusted all-cause mortality at Day 60. Safety findings were comparable between otilimab and placebo, and consistent with severe COVID-19. Although not statistically significant in the overall population, otilimab demonstrated a substantial benefit in patients aged \u226570, possibly reflecting a population that could benefit from therapeutic blocking of GM-CSF in severe COVID-19 where myeloid cell dysregulation is predominant.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>A Randomized Trial of Otilimab in Severe COVID-19 Pneumonia (OSCAR) https:\/\/www.medrxiv.org\/content\/10.1101\/2021.04.14.21255475v1 NCT04376684- Overall, 806 patients were randomized (1:1); 71% of patients receiving otilimab were alive and free of respiratory failure at Day 28 versus 67% receiving placebo, although this did&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/18-apr-2021-otilimab-demonstrated-a-substantial-benefit-in-severe-covid-patients\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(18 Apr 2021) Otilimab- demonstrated a substantial benefit in severe COVID patients&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[6,126],"tags":[127],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/988"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=988"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/988\/revisions"}],"predecessor-version":[{"id":989,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/988\/revisions\/989"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=988"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=988"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=988"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}